StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Gain Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$18.95M. For fiscal 2025 it was -$18.47M. The highest annual figure on record is -$3.24M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.47M–
FY2024Dec 31, 2024-$18.87M–
FY2023Dec 31, 2023-$18.87M–
FY2022Dec 31, 2022-$14.69M–
FY2021Dec 31, 2021-$12.37M–
FY2020Dec 31, 2020-$3.24M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.68M–
Q1 FY2026Mar 31, 2026-$4.73M–
Q4 FY2025Dec 31, 2025-$4.62M–
Q3 FY2025Sep 30, 2025-$4.93M–
Q2 FY2025Jun 30, 2025-$5.10M–
Q1 FY2025Mar 31, 2025-$3.82M–
Q4 FY2024Dec 31, 2024-$3.45M–
Q3 FY2024Sep 30, 2024-$6.08M–
Q2 FY2024Jun 30, 2024-$5.76M–
Q1 FY2024Mar 31, 2024-$3.59M–
Q4 FY2023Dec 31, 2023-$5.66M–
Q3 FY2023Sep 30, 2023-$3.97M–
Q2 FY2023Jun 30, 2023-$5.02M–
Q1 FY2023Mar 31, 2023-$4.22M–
Q4 FY2022Dec 31, 2022-$3.90M–
Q3 FY2022Sep 30, 2022-$3.29M–
Q2 FY2022Jun 30, 2022-$5.05M–
Q1 FY2022Mar 31, 2022-$2.45M–
Q4 FY2021Dec 31, 2021-$4.15M–
Q3 FY2021Sep 30, 2021-$2.19M–
Q2 FY2021Jun 30, 2021-$3.22M–
Q1 FY2021Mar 31, 2021-$2.81M–
Q4 FY2020Dec 31, 2020-$1.31M–
Q3 FY2020Sep 30, 2020-$755.02K–
Q2 FY2020Jun 30, 2020-$424.19K–
Q1 FY2020Mar 31, 2020-$752.82K–

More Gain Therapeutics figures

See a number that looks wrong?